Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 2
2009 2
2010 2
2012 1
2013 1
2016 2
2018 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults.
Graziano S, Boldrini F, Pellicano GR, Milo F, Majo F, Cristiani L, Montemitro E, Alghisi F, Bella S, Cutrera R, Fiocchi AG, Quittner A, Tabarini P. Graziano S, et al. Among authors: bella s. Chest. 2024 Apr;165(4):800-809. doi: 10.1016/j.chest.2023.10.043. Epub 2023 Nov 3. Chest. 2024. PMID: 37925143
May the new suggested lower borderline limit of sweat chloride impact the diagnostic process for cystic fibrosis?
Cirilli N, Braggion C, Mergni G, Polizzi AM, Padoan R, Sirianni S, Seia M, Raia V, Tosco A, Pisi G, Spaggiari C, Quattromano E, Bignamini E, Brandino D, Bella S, Argentini R; ICFS Sweat Test Working Group. Cirilli N, et al. Among authors: bella s. J Pediatr. 2018 Mar;194:261-262. doi: 10.1016/j.jpeds.2017.11.053. Epub 2018 Jan 17. J Pediatr. 2018. PMID: 29352589 No abstract available.
Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate.
Bianchi ML, Colombo C, Assael BM, Dubini A, Lombardo M, Quattrucci S, Bella S, Collura M, Messore B, Raia V, Poli F, Bini R, Albanese CV, De Rose V, Costantini D, Romano G, Pustorino E, Magazzù G, Bertasi S, Lucidi V, Traverso G, Coruzzo A, Grzejdziak AD. Bianchi ML, et al. Among authors: bella s. Lancet Respir Med. 2013 Jul;1(5):377-85. doi: 10.1016/S2213-2600(13)70064-X. Epub 2013 Jun 2. Lancet Respir Med. 2013. PMID: 24429202 Clinical Trial.
13 results